Sanofi-owned Aventis Pharma has received approval for its type 1 diabetes (T1D) drug, Tzield (teplizumab), from the UK Medicines and Healthcare products Regulatory Agency (MHRA). This authorisation ...

The application seeks approval for Tzield (teplizumab-mzwv) to delay the progression of stage 3 type 1 diabetes in adults and pediatric patients eight years and older who have been recently diagnosed ...

Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes Approval based on the TN-10 study, demonstrating Tzield’s ability to delay the ...